NCT01601990 - Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

189

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

November 30, 2011

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Placebo group(once daily)

eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.

DRUG

LC15-0444 50mg qd

eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks

Trial Locations (1)

LG Life Sciences, Seoul